KBY Biotech Indexv0.0.34
Search
← Pipeline|Lisotapinarof

Lisotapinarof

Approved
GYR-8970
By Gyre Ther
Source: Trial-derived·Trials: 4
Modality
Radioligand
MOA
IL-23i
Target
IL-17A
Pathway
Fibrosis
Crohn'sMelanomaEwing Sarcoma
Development Pipeline
Preclinical
~Dec 2009
→ ~Mar 2011
Phase 1
~Jun 2011
→ ~Sep 2012
Phase 2
~Dec 2012
→ ~Mar 2014
Phase 3
~Jun 2014
→ ~Sep 2015
NDA/BLA
~Dec 2015
→ ~Mar 2017
Approved
Jun 2017
→ Oct 2030
ApprovedCurrent
NCT08054158
1,530 pts·Melanoma
2017-11→2026-06·Recruiting
NCT08429386
572 pts·Melanoma
2022-08→2028-07·Completed
NCT07468733
437 pts·Melanoma
2017-06→2028-09·Recruiting
+1 more trial
3,422 total pts2 indications
CompletedCurrentUpcoming
Catalysts (4)
2026-06-122mo awayPh3 Readout· Melanoma
2028-07-032.3y awayPh3 Readout· Melanoma
2028-09-172.5y awayPh3 Readout· Melanoma
2030-10-094.5y awayPh3 Readout· Ewing Sarcoma
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Recruit…
Approved
Recruit…
Approved
Complet…
Approved
Not yet…
Catalysts
Ph3 Readout
2026-06-12 · 2mo away
Melanoma
Ph3 Readout
2028-07-03 · 2.3y away
Melanoma
Ph3 Readout
2028-09-17 · 2.5y away
Melanoma
Ph3 Readout
2030-10-09 · 4.5y away
Ewing Sarcoma
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT08054158ApprovedMelanomaRecruiting1530eGFR
NCT08429386ApprovedMelanomaCompleted572DOR
NCT07468733ApprovedMelanomaRecruiting437EASI-75
NCT06964685ApprovedEwing SarcomaNot yet recr...883NT-proBNP
Competitors (10)
DrugCompanyPhaseTargetMOA
GeliderotideNovartisNDA/BLAIL-17ABCL-2i
GSK-6983GSKPhase 2ALKIL-23i
MotarapivirGSKPreclinicalAuroraAIL-23i
TirasotorasibTakedaNDA/BLAIL-17ACDK2i
GIL-9779Gilead SciencesPhase 1IL-17ABCMA ADC
ZenotapinarofVertex PharmaPreclinicalCD38IL-23i
BemasotorasibExelixisPhase 2CD38IL-23i
RVM-7089Revolution MedicinesPhase 3IL-17AMALT1i
TirasotorasibViking TherapeuticsPhase 1CFTRIL-23i
AdagrarapivirIdeaya BioPhase 1/2IL-17AHER2